Logo image
Detection of membrane and soluble interleukin‐6 receptor in lymphoid malignancies
Article de revue scientifique   Avec comité de lecture

Detection of membrane and soluble interleukin‐6 receptor in lymphoid malignancies

Thierry Lavabre-Bertrand, Carole Exbrayat, Jeannie Liautard, Jean‐Philippe Gaillard, Pierre‐Paul Baskevitch, Nicolas Poujol, Christophe Duperray, Pascal Bourqoard et Jean Brochier
British journal of haematology, Vol.91(4), p.871-877
12/1995
PMID: 8547132

Résumé

chronic lymphocytic leukaemia interleukin‐6 receptor non‐Hodgkin's lymphoma
We studied the membrane expression of the gp80 chain of IL‐6 receptor (IL‐6R) by quantitative flow cytometry in chronic lymphocytic leukaemia (CLL) and leukaemic centrocytic lymphoma using a panel of seven monoclonal antibodies. IL‐6R was detected in 18/26 CLL cases and 4/7 lymphoma cases, with a mean antigen density <3000 molecules/cell. Multiple labelling experiments confirmed the IL‐6R expression by neoplastic cells. Specific mRNA was found by RT‐PCR in neoplastic cells. A specific ELISA test was designed using two anti‐IL‐6 receptor MAbs to measure the serum soluble IL‐6R (sIL‐6R) in CLL (n = 48), B‐cell non‐Hodgkin's lymphoma (NHL; n = 40), and monoclonal gammopathy (MG; n = 32). SIL‐6R was higher in CLL (170±12.6ng/ml) in NHL (160 ± 12ng/ml) and MG patients (183±23ng/ml) than in age‐matched controls (100 ±5.6 ng/ml; P < 0.001) and higher in high‐grade than low‐grade NHL. No correlation was noted with a previous treatment. Among CLL cases the patients classified as stage B according to the Binet's staging of the disease had the highest sIL‐6R values, thus suggesting a link with tumour cell mass.

Indicateurs

1 Consultations de la notice

Détails

Logo image